Evidence map›Paper›PMID 35935020›Full record

ArticleFrontiers in allergy2022

Efficacy and safety of omalizumab therapy in urticaria vasculitis.

Fiorella Petrelli, Daiana Giannini, Silvia Bilia, Isabella Del Corso, Valeria Rocchi, Paola Migliorini, Ilaria Puxeddu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Fiorella PetrelliImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Daiana GianniniImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Silvia BiliaImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Isabella Del CorsoImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Valeria RocchiImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Paola MiglioriniImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
Ilaria PuxedduImmunoallergology Unit, Department of Clinical and Experimental Medicine, Pisa University, Pisa, Italy.
University of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Urticarial vasculitis (UV) is a small-vessel leukocytoclastic vasculitis characterized by different clinical manifestations ranging from long-lasting urticarial lesions to severe and potentially life-threatening multi-organ involvement. Omalizumab (OMA), anti-IgE recombinant humanized IgG1 monoclonal antibody, has been successfully used to treat few cases of severe and/or refractory UV. In this study we report our experience on 6 patients with refractory normocomplementemic UV successfully treated with anti-IgE therapy (OMA), suggesting that this biological therapy may be a safe and effective therapeutic option in UV.

Indexed as

anti IgEbiological agentomalizumabtherapyurticarial vasculitis

Identifiers

PMID35935020
PMCPMC9353047
OpenAlexW4286447815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.